Xenon Pharmaceuticals Inc.
XENE
$55.23
-$2.67-4.61%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 43.04% | 42.04% | 42.00% | 31.99% | 25.60% |
| Gross Profit | -39.47% | -38.13% | -37.78% | -27.63% | -25.60% |
| SG&A Expenses | 15.57% | 18.97% | 22.44% | 41.22% | 48.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.26% | 36.30% | 37.09% | 34.12% | 30.48% |
| Operating Income | -33.57% | -33.37% | -33.93% | -30.78% | -30.48% |
| Income Before Tax | -44.66% | -44.83% | -41.76% | -35.36% | -30.51% |
| Income Tax Expenses | 124.85% | -655.61% | -1,443.11% | -2,296.47% | -1,300.34% |
| Earnings from Continuing Operations | -47.62% | -43.56% | -39.77% | -33.32% | -28.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.62% | -43.56% | -39.77% | -33.32% | -28.48% |
| EBIT | -33.57% | -33.37% | -33.93% | -30.78% | -30.48% |
| EBITDA | -33.89% | -33.79% | -34.99% | -31.82% | -31.46% |
| EPS Basic | -44.99% | -38.30% | -29.45% | -18.59% | -10.19% |
| Normalized Basic EPS | -42.10% | -39.42% | -30.82% | -19.25% | -9.77% |
| EPS Diluted | -44.99% | -38.30% | -29.45% | -18.59% | -10.19% |
| Normalized Diluted EPS | -42.10% | -39.42% | -30.82% | -19.25% | -9.77% |
| Average Basic Shares Outstanding | 1.74% | 4.00% | 7.80% | 11.90% | 16.45% |
| Average Diluted Shares Outstanding | 1.74% | 4.00% | 7.80% | 11.90% | 16.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |